Comparison of the anticoagulant effect of a direct thrombin inhibitor and a low molecular weight heparin in an acquired antithrombin deficiency in children with acute lymphoblastic leukaemia treated withl-asparaginase: an in vitro study

Authors: Kuhle, Stefan; Lau, Alice¹; Bajzar, Laszlo²; Vegh, Patsy¹; Halton, Jacqueline³; Cherrick, Irene⁴; Anderson, Ron⁵; Desai, Sunil⁶; McCusker, Patricia; Wu, John⁷; Abshire, Thomas⁸; Mahoney, Donald⁹; Mitchell, Lesley²

Source: British Journal of Haematology, Volume 134, Number 5, September 2006 , pp. 526-531(6)

Publisher: Blackwell Publishing

Key:

- Free Content

- New Content

- Subscribed Content

- Free Trial Content

Abstract:

Summary

Thrombosis occurs in 37% of children with acute lymphoblastic leukaemia (ALL) and is related to anl-asparaginase-induced acquired antithrombin (AT) deficiency. The incidence dictates the need for anticoagulant prophylaxis. Direct thrombin inhibitors (DTI) are independent of AT for effect and may thus have advantages in this population. The objective of this study was to determine the interaction of an AT deficiency with the anticoagulant effects of a DTI and a low molecular weight heparin (LMWH). Plasma samples from children with ALL were pooled (mean AT 0·53 U/ml). LMWH 0·3 and 0·7 U/ml or melagatran 0·3 and 0·5 μmol/l were added to the pools, then divided and AT was added back to one aliquot. In additional experiments, AT was added to AT immuno-depleted plasma. Endogenous thrombin generation capacity (ETGC) was assessed by the continuous method. In plasma with LMWH, there was a 66-88% decrease in ETGC in AT-normalised samples compared with neat. Conversely, no significant difference in ETGC with or without AT added for melagatran was seen. Experiments with AT-depleted plasma showed no effect of AT level on anticoagulant activity of DTI, but a significant relationship for LMWH. By contrast to LMWH, DTI provides a consistent anticoagulant response independent of AT levels in children with AT deficiency.

Keywords: children; direct thrombin inhibitors; low molecular weight heparin; antithrombin deficiency; thrombin generation

Document Type: Research article

DOI: 10.1111/j.1365-2141.2006.06209.x

Affiliations: 1: Department of Population Health, The Hospital for Sick Children, Toronto, ON 2: Pediatric Thrombosis Program, Stollery Children's Hospital, Edmonton, AB 3: Department of Hematology/Oncology, Children's Hospital of Eastern Ontario, Ottawa, ON, Canada 4: Department of Hematology/Oncology, Upstate Medical University, Syracuse, NY, USA 5: Department of Hematology/Oncology, Alberta Children's Hospital, Calgary, AB 6: Department of Hematology, Stollery Children's Hospital, Edmonton, AB 7: Department of Oncology, Hematology and BMT, BC Children's Hospital, Vancouver, BC, Canada 8: Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 9: Department of Hematology, Texas Children's Hospital, Houston, TX, USA

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$50.16 plus tax Refund Policy

Key:

- Free Content

- New Content

- Subscribed Content

- Free Trial Content

Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages.